May 23 Could Bring Approval for Vertex's Hep C Drug

[Guest guest]

May 23 Could Bring Approval for Vertex's Hep C Drug

Due to a solid Phase III program, Vertex's telaprevir (Incivek) could receive approval to treat Hepatitis C before the end of May 2011.

Vertex Pharma Hepatitis C Drug Incivek Likely to be Approved by May 23: Analyst

By IB Times Staff Reporter | May 4, 2011

RBC Capital Markets expects Vertex Pharmaceuticals Inc.'s (NASDAQ: VRTX) Incivek (telaprevir) to treat hepatitis C is likely to be approved on or around May 23.

"Once approved, we believe near-term performance in Vertex shares will be tied to launch metrics and continued progress in its pipeline including its Cystic Fibrosis (CF) drugs. We continue to believe that Incivek will receive a clean, broad label, including a simple treatment algorithm and side-effect management program," said Kantor, an analyst at RBC Capital Markets.

Continue reading this entire article:http://www.ibtimes.com/articles/141143/20110504/vertex-pharmaceuticals-incivek-telaprevir-hepatitis-c-cystic-fibrosis-drug-rbc-capital-markets-nasda.htm

http://www.hepatitis-central.com/mt/archives/2011/05/may_23_could_br.html